A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
A phase 2 trial of Rocbrutinib in mantle cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., active and no longer recruiting.
Overview
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05716087 by Guangzhou Lupeng Pharmaceutical Company LTD., with 62 participants planned, started 2023-02-21 and due to reach its primary completion in 2024-12-05. Interventions recorded: Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
Setting
An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma
Phase
Phase 2
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Registry
Enrolled
62
Similar pages
not linked directly; found by shared links- TrialA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Shares Rocbrutinib, Mantle cell lymphoma.
- TrialA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Shares Rocbrutinib, Mantle cell lymphoma.